04-12-2023 05:11 PM | Source: Reuters
India`s SII could resume Covishield shot production as COVID cases rise
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.
The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added. Covishield is a version of an AstraZeneca shot.
Latest News
Centre launches portal for nurturing skill developme...
Hyundai, Kia`s Europe sales down 7.5 pc in October
AI-powered voice analysis may revolutionise early di...
Rohit Sharma to join Indian team in Australia on Sunday
Evening Roundup : A Daily Report on Bullion Energy &...
Buy Copper Above 825 SL Below 821 TGT 830/833 - Axis...
Over 9 in 10 Indian leaders anticipate an increase i...
Evening Track : Renewed Geopolitical uncertainty fue...
Mahayuti government is going to be formed: Shiv Sena...
Everything will get clear on the 23rd: BJPs Rahul Na...
